Welcome to our dedicated page for Predictive Oncology SEC filings (Ticker: POAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Predictive Oncology Inc. (NASDAQ: POAI), which is changing its name to Axe Compute Inc. with an expected ticker change to AGPU, provides access to the company’s official regulatory disclosures. These documents include current reports on Form 8‑K, proxy statements, and other filings that describe material events, governance decisions, financing transactions, and listing matters.
Recent Form 8‑K filings detail several key developments. One 8‑K reports the adoption of a digital asset treasury strategy supported by private placements involving cash and in‑kind contributions of ATH, the native utility token of the Aethir ecosystem. Other 8‑Ks describe the launch and terms of these private placements, related registration rights agreements, and the use of proceeds to acquire ATH and support working capital and general corporate purposes. Additional 8‑Ks cover the 1‑for‑15 reverse stock split of the company’s common stock, actions taken to address Nasdaq listing requirements, and the company’s belief that it has regained compliance with Nasdaq’s minimum stockholders’ equity requirement.
The filings also document corporate governance and shareholder matters. A definitive proxy statement on Schedule DEF 14A outlines proposals for the annual meeting, including the election of directors, ratification of the independent auditor, amendments to the 2024 Equity Incentive Plan, approval of the issuance of shares upon exercise of pre‑funded warrants, and a non‑binding advisory vote on executive compensation. Another 8‑K describes shareholder approval of these items and the resulting increase in shares available under the equity plan.
One notable 8‑K filing reports the corporate name change from Predictive Oncology Inc. to Axe Compute Inc., effective December 11, 2025, and states that the Nasdaq ticker symbol is expected to change from POAI to AGPU on or about December 12, 2025. The filing notes that outstanding stock certificates remain valid and that the CUSIP number for the common stock will not change in connection with the name change.
Through Stock Titan, users can review these SEC filings in sequence and, with AI‑powered summaries, quickly understand the implications of complex documents such as 8‑Ks, proxy statements, and registration‑related supplements. This includes identifying how financing structures, equity plans, reverse splits, and digital asset strategies affect the company’s capital structure and governance over time.
Predictive Oncology Inc. filed a prospectus supplement to its existing S-3 ATM program, updating the amount it may sell under General Instruction I.B.6. As of October 29, 2025, the company may offer and sell common stock with an aggregate offering price of up to $18,330,000 through H.C. Wainwright & Co. as sales agent.
The filing notes the I.B.6 framework, allowing primary offerings up to one-third of public float and removal of this limit if public float exceeds $75.0 million. It also states that approximately $2,417,337 of securities were sold under I.B.6 during the prior 12 months.
Predictive Oncology (POAI) filed a prospectus supplement for an at-the-market offering of up to $18,330,000 of common stock under its agreement with H.C. Wainwright, subject to General Instruction I.B.6 limits.
Over the last 12 months, the company sold 139,680 shares for aggregate gross proceeds of approximately $1,872,333 through the ATM. As calculated within 60 days of this supplement, public float was $62,257,699, based on 3,458,934 non‑affiliate shares at $17.9991. The company noted $2,417,337 of securities sold pursuant to I.B.6 in the same period. If public float rises above $75.0 million, the I.B.6 cap would no longer apply; additional capacity would be reflected in a future supplement.
As of October 28, 2025, the company held approximately 5.49 billion Aethir tokens valued at about $159.2 million based on a $0.0290 price.
Predictive Oncology Inc. (POAI) set its Annual Meeting for November 25, 2025 to vote on key items including board elections, auditor ratification, equity plan changes, and a large share issuance tied to pre-funded warrants. Stockholders of record as of October 24, 2025 (3,501,430 shares outstanding) may vote.
The ballot seeks: (1) election of two Class I directors; (2) ratification of KPMG as independent auditor for fiscal 2025; (3) an amendment to the 2024 Equity Incentive Plan to lift the reserve from 66,667 to 1,066,667 shares and cap incentive stock options at 500,000; (4) approval, under Nasdaq Listing Rule 5635(a), of the issuance of 14,903,393 shares of common stock upon exercise of pre-funded warrants to purchase an equal number of shares; and (5) a non-binding say‑on‑pay vote.
The company notes an overhang of 1.5% as of October 13, 2025, which would rise to approximately 24% if the plan amendment to 1,066,667 shares is approved, before any additional shares from pre-funded warrant exercises. A quorum requires 1,167,144 shares present or represented by proxy.
Predictive Oncology Inc. filed a resale registration covering up to 5,970,181 shares of common stock, to be sold from time to time by the selling stockholders after effectiveness. The company is not offering any shares.
The registered amount includes 3,365,690 PIPE Shares issued in August and September private placements, plus 2,604,491 shares issuable upon warrant exercise, consisting of 1,037,250 Cash PIPE Warrant Shares, 218,335 Agent Warrant Shares, and 1,348,906 Advisor Warrant Shares.
No proceeds will go to the company from stockholder resales. The company would receive cash only upon warrant exercises. The Cash PIPE Warrants carry a nominal $0.01 per-share exercise price; Agent and Advisor Warrants are exercisable at $11.6265 per share. POAI trades on Nasdaq; the last reported price was $9.30 per share on October 21, 2025.
Predictive Oncology Inc. filed a resale registration covering up to 14,903,393 shares of common stock underlying pre-funded warrants issued under a September 29, 2025 securities purchase agreement. The shares may be sold from time to time by the selling stockholders named in the prospectus.
The company is not offering any shares and will not receive proceeds from sales by the selling stockholders; it would receive only any cash paid upon warrant exercise. The warrants carry a $0.01 per share exercise price, have no expiration, and include a 19.99% beneficial ownership limitation. Exercise of these warrants is subject to shareholder approval for the underlying share issuance.
As context, the company’s Nasdaq ticker is POAI, and the last reported sale price was $9.30 per share on October 21, 2025. The filing notes a recent 1-for-15 reverse stock split effective September 30, 2025, and outlines a separate cash PIPE and a crypto-funded PIPE that introduced these pre-funded warrants. The plan of distribution permits various sale methods by the selling holders.
Predictive Oncology Inc. (POAI) filed a Form 3 for a director, the initial statement of beneficial ownership under Section 16. The filing states no securities are beneficially owned as of the event date 10/07/2025. The submission includes an Exhibit 24.1 Power of Attorney, and was signed by Josh Blacher, Attorney-in-Fact. This is an administrative disclosure and does not reflect a transaction.
Predictive Oncology (POAI)no securities are beneficially owned as of the event date 10/08/2025.
The filing includes Exhibit 24.1, a Power of Attorney, and was submitted as a single‑person filing.
Predictive Oncology set its 2025 annual meeting for November 25, 2025, in Pittsburgh at DLA Piper LLP (US). Stockholders of record on October 24, 2025 will be entitled to vote.
Stockholder proposals and proxy access requests must be received by October 26, 2025. The company expects to mail definitive proxy materials on or about November 3, 2025 and may supplement those materials, and if necessary postpone the meeting, to address any timely proposals.
Predictive Oncology Inc. filed an 8-K describing a press release issued on October 8, 2025. The release announced the closing of two private placements on October 7, 2025 and the company’s adoption of a digital asset treasury strategy, signaling a change in how it may hold part of its treasury assets. The press release is furnished under Regulation FD and attached as Exhibit 99.1, with most of its content (excluding the fifth and sixth paragraphs) also treated as an “Other Event” disclosure.
FAQ
What is the current stock price of Predictive Oncology (POAI)?
What is the market cap of Predictive Oncology (POAI)?
